Pflugfelder, Annette and Kochs, Corinna and Blum, Andreas and Capellaro, Marcus and Czeschik, Christina and Dettenborn, Therese and Dill, Dorothee and Dippel, Edgar and Eigentler, Thomas and Feyer, Petra and Follmann, Markus and Frerich, Bernhard and Ganten, Maria-Katharina and Gaertner, Jan and Gutzmer, Ralf and Hassel, Jessica and Hauschild, Axel and Hohenberger, Peter and Huebner, Jutta and Kaatz, Martin and Kleeberg, Ulrich R. and Koelbl, Oliver and Kortmann, Rolf-Dieter and Krause-Bergmann, Albrecht and Kurschat, Peter and Leiter, Ulrike and Link, Hartmut and Loquai, Carmen and Loeser, Christoph and Mackensen, Andreas and Meier, Friedegund and Mohr, Peter and Moehrle, Matthias and Nashan, Dorothee and Reske, Sven and Rose, Christian and Sander, Christian and Satzger, Imke and Schiller, Meinhard and Schlemmer, Heinz-Peter and Strittmatter, Gerhard and Sunderkoetter, Cord and Swoboda, Lothar and Trefzer, Uwe and Voltz, Raymond and Vordermark, Dirk and Weichenthal, Michael and Werner, Andreas and Wesselmann, Simone and Weyergraf, Ansgar J. and Wick, Wolfgang and Garbe, Claus and Schadendorf, Dirk (2013) Malignant Melanoma S3-Guideline "Diagnosis, Therapy and Follow-up of Melanoma". JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 11. pp. 1-116. ISSN 1610-0379, 1610-0387
Full text not available from this repository.Abstract
This first German evidence-based guideline for cutaneous melanoma was developed under the auspices of the German Dermatological Society (DDG) and the Dermatologic Cooperative Oncology Group (DeCOG) and funded by the German Guideline Program in Oncology. The recommendations are based on a systematic literature search, and on the consensus of 32 medical societies, working groups and patient representatives. This guideline contains recommendations concerning diagnosis, therapy and follow-up of melanoma. The diagnosis of primary melanoma based on clinical features and dermoscopic criteria. It is confirmed by histopathologic examination after complete excision with a small margin. For the staging of melanoma, the AJCC classification of 2009 is used. The definitive excision margins are 0.5 cm for in situ melanomas, 1 cm for melanomas with up to 2 mm tumor thickness and 2 cm for thicker melanomas, they are reached in a secondary excision. From 1 mm tumor thickness, sentinel lymph node biopsy is recommended. For stages II and III, adjuvant therapy with interferon-alpha should be considered after careful analysis of the benefits and possible risks. In the stage of locoregional metastasis surgical treatment with complete lymphadenectomy is the treatment of choice. In the presence of distant metastasis mutational screening should be performed for BRAF mutation, and eventually for CKIT and NRAS mutations. In the presence of mutations in case of inoperable metastases targeted therapies should be applied. Furthermore, in addition to standard chemotherapies, new immunotherapies such as the CTLA-4 antibody ipilimumab are available. Regular follow-up examinations are recommended for a period of 10 years, with an intensified schedule for the first three years.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | SENTINEL LYMPH-NODE; QUALITY-OF-LIFE; HIGH-RISK MELANOMA; COOPERATIVE-ONCOLOGY-GROUP; PRIMARY CUTANEOUS MELANOMA; RANDOMIZED PHASE-III; ISOLATED LIMB PERFUSION; STAGE-IV MELANOMA; POSITRON-EMISSION-TOMOGRAPHY; AMERICAN-JOINT-COMMITTEE; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Strahlentherapie |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 03 Apr 2020 07:26 |
| Last Modified: | 03 Apr 2020 07:26 |
| URI: | https://pred.uni-regensburg.de/id/eprint/16268 |
Actions (login required)
 |
View Item |
